Literature DB >> 30197441

Post-surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003-2015).

Travis Laver1, Brittany R Feldhaeusser1, Cecilia S Robat1, Jennifer L Baez1, Kim L Cronin1, Paolo Buracco1, Maurizio Annoni1, Rebecca C Regan1, Sarah K McMillan1, Kaitlin M Curran1, Laura E Selmic1, Kai-Biu Shiu1, Kyle Clark1, Erin Fagan1, Douglas H Thamm1.   

Abstract

The medical records of 87 dogs treated with surgery for cutaneous malignant melanoma (CMM) of the haired skin were retrospectively reviewed for overall survival time (OST), progression-free survival time (PFS), and prognostic factors. The post-surgery median PFS and median OST were 1282 days and 1363 days, respectively. The post-surgery metastatic rate was 21.8% with a local recurrence rate of 8%. Increasing mitotic index (MI) was predictive of a significantly decreased OST and PFS on multivariable analysis [hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.02 to 1.07 and HR: 1.04, 95% CI: 1.02 to 1.06, respectively]. Increasing age was likewise predictive of a significantly decreased OST and PFS on multivariable analysis (HR: 1.39, 95% CI: 1.17 to 1.65 and HR: 1.33, 95% CI: 1.14 to 1.54, respectively). These results confirm clinical impressions that long survival times are likely in dogs diagnosed with malignant melanoma of the haired skin when treated with surgery alone.

Entities:  

Mesh:

Year:  2018        PMID: 30197441      PMCID: PMC6091115     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  16 in total

1.  Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011).

Authors:  Joanne L Tuohy; Laura E Selmic; Deanna R Worley; Nicole P Ehrhart; Stephen J Withrow
Journal:  J Am Vet Med Assoc       Date:  2014-12-01       Impact factor: 1.936

Review 2.  Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation.

Authors:  R C Smedley; W L Spangler; D G Esplin; B E Kitchell; P J Bergman; H-Y Ho; I L Bergin; M Kiupel
Journal:  Vet Pathol       Date:  2011-01       Impact factor: 2.221

3.  Canine cutaneous melanocytic tumours: significance of β-catenin and survivin immunohistochemical expression.

Authors:  Laura Bongiovanni; Alessandra D'Andrea; Ilaria Porcellato; Andrea Ciccarelli; Daniela Malatesta; Mariarita Romanucci; Leonardo Della Salda; Luca Mechelli; Chiara Brachelente
Journal:  Vet Dermatol       Date:  2015-05-12       Impact factor: 1.589

4.  A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.

Authors:  J M Ottnod; R C Smedley; R Walshaw; J G Hauptman; M Kiupel; J E Obradovich
Journal:  Vet Comp Oncol       Date:  2013-09       Impact factor: 2.613

5.  Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs.

Authors:  Patricia C Schultheiss
Journal:  J Vet Diagn Invest       Date:  2006-07       Impact factor: 1.279

6.  Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.

Authors:  L K Brockley; M A Cooper; P F Bennett
Journal:  N Z Vet J       Date:  2012-08-23       Impact factor: 1.628

7.  Correlation between prognostic factors and increasing age in melanoma.

Authors:  Celia Chao; Robert C G Martin; Merrick I Ross; Douglas S Reintgen; Michael J Edwards; R Dirk Noyes; Lee J Hagendoorn; Arnold J Stromberg; Kelly M McMasters
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

Review 8.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

9.  Prognosis after surgical excision of canine melanomas.

Authors:  D E Bostock
Journal:  Vet Pathol       Date:  1979-01       Impact factor: 2.221

10.  Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012).

Authors:  Sarah E Boston; Xiaomin Lu; William T N Culp; Vincenzo Montinaro; Giorgio Romanelli; Robert M Dudley; Julius M Liptak; Lisa A Mestrinho; Paolo Buracco
Journal:  J Am Vet Med Assoc       Date:  2014-08-15       Impact factor: 1.936

View more
  3 in total

1.  Prevalence and Clinicopathologic Features of Canine Metastatic Melanoma Involving the Central Nervous System: A Retrospective Analysis and Comparative Review.

Authors:  Aryana M Razmara; Luke A Wittenburg; Sami Al-Nadaf; Ryan G Toedebusch; Frederick J Meyers; Christine M Toedebusch
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

2.  Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.

Authors:  Elizabeth A Wood; Zhanping Lu; Shuai Jia; Anna L F V Assumpção; Matthew A Van Hesteren; Mike K Huelsmeyer; David M Vail; Xuan Pan
Journal:  Vet Comp Oncol       Date:  2019-10-30       Impact factor: 2.613

Review 3.  Diagnosis and Prognosis of Canine Melanocytic Neoplasms.

Authors:  Rebecca C Smedley; Kimberley Sebastian; Matti Kiupel
Journal:  Vet Sci       Date:  2022-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.